EGFR and glioblastoma: Similar effects were seen upon local application of NK-92 cells equipped with CARs that recognize EGFR, mutant EGFRvIII, or both antigens against orthotopic EGFR- and/or EGFRvIII-positive glioblastoma xenografts or breast cancer brain metastases growing in NSG mice (70–72).